Zydus US020
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cruz, Mandy
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis

Recruiting
3
150
US, RoW
Saroglitazar Magnesium 1 mg
Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/27
07/27
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Active, not recruiting
2/3
186
NA
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
05/25
05/25
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis

Active, not recruiting
2
180
US, RoW
Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent
Zydus Therapeutics Inc.
Nonalcoholic Steatohepatitis, Fibrosis
07/25
07/25
NCT05045482: Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease

Recruiting
1
24
US
Saroglitazar Magnesium 1 mg, Subjects will be domicile in clinic from Day -1 till Day 5 or Day 7 and from Day 27 through day 29 for PK sampling procedures., Saroglitazar Magnesium 2 mg
Zydus Therapeutics Inc.
Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
11/24
11/24
NCT04454463: Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

Active, not recruiting
N/A
1640
US
Johns Hopkins Bloomberg School of Public Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Baylor College of Medicine, Case Western Reserve University, Duke University, Ann & Robert H Lurie Children's Hospital of Chicago, Indiana University, Liver Institute Northwest, Seattle Children's Hospital, St. Louis University, University of California, San Diego, University of California, San Francisco, University of Southern California, Virginia Commonwealth University, Emory University, Children's Hospital Medical Center, Cincinnati
Liver Diseases
06/25
06/25
Pritchard, Natalie
NCT04638647 / 2020-004284-98: Secukinumab Open Label Roll-over Extension Protocol

Recruiting
4
715
Europe, US, RoW
Secukinumab s.c. injection
Novartis Pharmaceuticals
Autoimmunity, Inflammation
12/27
02/28
NCT05603754: A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

Completed
3
496
US
Lorecivivint, SM04690, Placebo, Vehicle
Biosplice Therapeutics, Inc., NBCD A/S
Knee Osteoarthritis
02/24
02/24
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis

Active, not recruiting
2
180
US, RoW
Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent
Zydus Therapeutics Inc.
Nonalcoholic Steatohepatitis, Fibrosis
07/25
07/25

Download Options